Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7231-7240 Newer>

The Motley Fool March 4, 2011 Andrew Sullivan	Emdeon: Making Health Care More Efficient Meet a leader in this increasingly important industry.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool March 4, 2011 Brian Orelli	Up 15% for That? InterMune investors react to a non-event.
BusinessWeek March 3, 2011 Vekshin & Armstrong	Sebelius and DeParle Keep Health Reform Going Obama's HHS Secretary and Deputy Chief of Staff are granting companies and states generous waivers to ensure full implementation by 2014
The Motley Fool March 3, 2011 Brian Orelli	Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza.
The Motley Fool March 3, 2011 Bryan Hinmon	Medtronic's Moat Is Strengthening Lessons from an interview with Medtronic CFO Gary Ellis.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool March 3, 2011 Brian D. Pacampara	Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool March 2, 2011	Fool Q&A: Medtronic CFO Gary Ellis The medical-device maker's chief financial officer talks R&D, "One Medtronic," and growth in emerging markets.
<Older 7231-7240 Newer> Return to current articles.